Clinical Trials Logo
  1. Home
  2. Vaso-occlusive Crisis
  3. NCT03639805

Music Therapy in Sickle Cell Disease Vaso-occlusive Crisis — MUSICODREP  

Vaso-occlusive Crisis Clinical Trial

Official title:
Effect of a Music Therapy Program on Vaso-occlusive Crisis Pain in Sickle Cell Disease Patients: A Pilot Study

Clinical Trial Summary

Treatment of painful vaso-occlusive crises, the most common manifestation of sickle cell disease, is notoriously limited. vaso-occlusive crises pain is multifactorial with a psychological component. The hypothesis is that the music therapy program MUSIC CARE® can help alleviate severe vaso-occlusive crises pain in synergy with traditional treatment in sickle cell disease patients. The main objective of this prospective, randomized, open label study is to test the effect of the music therapy program MUSIC CARE® on daily mean morphine consumption during the 3 first days of hospitalisation for severe vaso-occlusive crises.

Clinical Trial Description

Sickle cell disease, the most frequent monogenic disease in France and in the world, is induced by a mutation in the β-globin chain of hemoglobin with production of hemoglobin S. The course of the disease is characterized by very painful, for which treatment is notoriously limited. vaso-occlusive crises pain is multifactorial with biological and psychological components. A few studies suggest a beneficial effect of relaxation techniques in the management of Sickle cell disease pain. MUSIC CARE® is a novative music therapy program which proved efficient in different models of acute or chronic pain. the hypothesis is that this program can help alleviate severe pain in synergy with traditional treatment in SS Sickle cell disease patients, via a dual biological and psychological effect. The main objective of this prospective, randomized, open label study is to test the effect of the music therapy program MUSIC CARE® on daily mean morphine consumption during the 3 first days of hospitalisation for severe vaso-occlusive crises in adult SS Sickle cell disease patients. Secondary outcomes will include mean daily Visual Analogic Scale during the first 3 days of hospitalization for severe vaso-occlusive crises, acute complications of vaso-occlusive crises, duration of severe vaso-occlusive crises and of hospitalization, Hospital Anxiety and Depression Scale.

20 patients will be included in each group for this pilot study. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT03639805
Study type Interventional
Source Assistance Publique - Hôpitaux de Paris
Contact Sylvain LE JEUNE, Dr
Phone 0148955149
Email sylvain.le-jeune@aphp.fr
Status Recruiting
Phase N/A
Start date September 28, 2018
Completion date April 28, 2020
View Details
See also
  Status Clinical Trial Phase
Withdrawn NCT00711698 - Comparison of Patient Controlled Analgesia (PCA) Versus Bolus Narcotic Therapy for the Treatment of Vaso-Occlusive Crisis (VOC) Phase 2
Recruiting NCT05289700 - Hyperbaric-oxygen Therapy (HBOT) Versus Placebo for Treating Vaso-Occlusive Crisis (VOC) in Sickle Cell Disease (SCD) Phase 3
Recruiting NCT03412045 - Hyperbaric Oxygen Therapy in Sickle Cell Pain N/A
Recruiting NCT05376046 - Study of Erythrocyte Parameters and Hypercoagulability in Sickle Cell Disease (SCD-TGA)
Active, not recruiting NCT04935879 - A Study to Assess the Safety and Efficacy of Inclacumab in Participants With Sickle Cell Disease Experiencing Vaso-occlusive Crises Phase 3
Terminated NCT01501643 - Non Invasive Positive Pressure Ventilation for Prevention of Acute Chest Syndrome in Sickle Cell Disease N/A
Terminated NCT01891812 - Nitrous Oxide Analgesia Vaso-occlusive Crisis Phase 2
Completed NCT04301336 - Different Treatment Modalities in the Management of the Painful Crisis in Pediatric Sickle- Cell Anemia Phase 2/Phase 3
Completed NCT01737814 - Evaluation of Purified Poloxamer 188 in Vaso-Occlusive Crisis of Sickle Cell Disease (EPIC) Phase 3
Completed NCT01419977 - Treatment of Sickle Cell Patients Hospitalized in Pain Crisis With Prophylactic Dose Low-molecular-weight Heparin (LMWH) Versus Placebo Phase 2
Completed NCT01119833 - Study of GMI-1070 for the Treatment of Sickle Cell Pain Crisis Phase 2
Not yet recruiting NCT06181695 - Intranasal Sufentanil for Analgesia of Severe Sickle Cell Vaso-occlusive Pain Crisis in the Pediatric Phase 3
Recruiting NCT05378555 - Oral Ketamine for Treatment of Vaso-Occlusive Pain Phase 3
Completed NCT04756375 - Evaluation of Virtual Reality to Save Morphinic in the Treatment of Vaso-occlusive Seizures of Sickle Cell Patients Consulting in the Emergency Room N/A
Recruiting NCT05348915 - A Study to Evaluate the Long-term Safety of Inclacumab Administered to Participants With Sickle Cell Disease Phase 3
Enrolling by invitation NCT06345638 - Sex Hormones and Inflammatory Biomarkers in Patients With Sickle Cell Disease
Completed NCT03296345 - Adjuvant Low-dose Ketamine in Pediatric Sickle Cell Vaso-occlusive Crisis Phase 2
Terminated NCT02179177 - Apixaban in Patients With Sickle Cell Disease Phase 3
Recruiting NCT03353584 - Effect of Virtual Reality Technology for Pain Management of Vaso-Occlusive Crisis in Patients With Sickle Cell Disease N/A
Terminated NCT01522196 - A Study of Varespladib Infusion in Subjects With Sickle Cell Disease. Phase 2